These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 3940216

  • 1. CB 1954 revisited. I. Disposition kinetics and metabolism.
    Workman P, White RA, Talbot K.
    Cancer Chemother Pharmacol; 1986; 16(1):1-8. PubMed ID: 3940216
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
    Kestell P, Pruijn FB, Siim BG, Palmer BD, Wilson WR.
    Cancer Chemother Pharmacol; 2000 Aug; 46(5):365-74. PubMed ID: 11127940
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988 Aug; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacokinetics of benznidazole.
    Workman P, White RA, Walton MI, Owen LN, Twentyman PR.
    Br J Cancer; 1984 Sep; 50(3):291-303. PubMed ID: 6466543
    [Abstract] [Full Text] [Related]

  • 6. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P.
    Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
    [Abstract] [Full Text] [Related]

  • 7. CB 1954 revisited. II. Toxicity and antitumour activity.
    Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR.
    Cancer Chemother Pharmacol; 1986 Sep; 16(1):9-14. PubMed ID: 3940225
    [Abstract] [Full Text] [Related]

  • 8. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
    Feun LG, Savaraj N, Lu K, Guo Z, Raulston LG, Benjamin RS, Fields WS, Loo TL.
    J Neurooncol; 1983 Sep; 1(3):219-24. PubMed ID: 6678971
    [Abstract] [Full Text] [Related]

  • 9. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
    Spiegel JF, Egorin MJ, Collins JM, Lerner BD, Bachur NR.
    Drug Metab Dispos; 1983 Sep; 11(1):41-6. PubMed ID: 6132794
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of diaziquone after three different dosage regimens.
    Bjornsson TD, Schold SC, Friedman HS, Schneider D, Falletta JM.
    Cancer Treat Rep; 1985 Dec; 69(12):1383-5. PubMed ID: 4075314
    [Abstract] [Full Text] [Related]

  • 11. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL.
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
    Workman P, Binger M, Kooistra KL.
    Int J Radiat Oncol Biol Phys; 1992 Apr; 22(4):713-6. PubMed ID: 1544843
    [Abstract] [Full Text] [Related]

  • 13. Enzyme-induced aziridine formation by rat liver microsomes.
    Hata Y, Watanabe M.
    Biochem Biophys Res Commun; 1983 Jan 14; 110(1):220-7. PubMed ID: 6838512
    [Abstract] [Full Text] [Related]

  • 14. The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).
    Jarman M, Melzack DH, Ross WC.
    Biochem Pharmacol; 1976 Nov 15; 25(22):2475-8. PubMed ID: 985569
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL, Vincent SH, Miller RR, Colletti AE, Alvaro RF, Wallace MA, Feeney WP, Chiu SH.
    Drug Metab Dispos; 1997 Oct 15; 25(10):1113-8. PubMed ID: 9321512
    [Abstract] [Full Text] [Related]

  • 16. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
    Evans SM, Young D, Robertson IG, Paxton JW.
    Cancer Chemother Pharmacol; 1992 Oct 15; 31(1):32-6. PubMed ID: 1458557
    [Abstract] [Full Text] [Related]

  • 17. A new metabolic reaction of diaziridines by rat liver microsomes.
    Hata Y, Watanabe M.
    Biochem Biophys Res Commun; 1982 May 31; 106(2):526-32. PubMed ID: 7104007
    [No Abstract] [Full Text] [Related]

  • 18. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems II: comparative pharmacokinetics in dogs.
    Lalka D, Jusko WJ, Bardos TJ.
    J Pharm Sci; 1975 Feb 31; 64(2):230-5. PubMed ID: 236372
    [No Abstract] [Full Text] [Related]

  • 19. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
    Egorin MJ, Bellis EH, Salcman M, Collins JM, Spiegel JF, Bachur NR.
    J Neurosurg; 1984 May 31; 60(5):1005-13. PubMed ID: 6716135
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.